Lv2
156 积分 2025-01-14 加入
Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK
1天前
已完结
Therapeutic landscape and future direction of metastatic colorectal cancer
2天前
已完结
Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics
7天前
已完结
Context-dependent synthetic lethality — an emerging precision therapeutic approach
7天前
已完结
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment
22天前
已完结
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
22天前
已完结
Targeting immunogenic cell stress and death for cancer therapy
1个月前
已完结
The therapeutic age of the neonatal Fc receptor
1个月前
已完结
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
1个月前
已完结
The landscape of small-molecule prodrugs
1个月前
已完结
皖公网安备34019202002308
